Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Baxter
Fuji
McKinsey
Mallinckrodt
Johnson and Johnson
Daiichi Sankyo
Queensland Health
Accenture
Fish and Richardson

Generated: January 21, 2018

DrugPatentWatch Database Preview

SODIUM NITROPRUSSIDE Drug Profile

« Back to Dashboard

Which patents cover Sodium Nitroprusside, and when can generic versions of Sodium Nitroprusside launch?

Sodium Nitroprusside is a drug marketed by Abraxis Pharm, Akorn, Amneal Pharms Co, Baxter Hlthcare, Namigen Llc, Nexus Pharms, and Teva Parenteral. and is included in seven NDAs.

The generic ingredient in SODIUM NITROPRUSSIDE is sodium nitroprusside. There are one thousand four hundred and fifteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the sodium nitroprusside profile page.
Drug patent expirations by year for SODIUM NITROPRUSSIDE
Pharmacology for SODIUM NITROPRUSSIDE
Drug ClassVasodilator
Physiological EffectVasodilation

US Patents and Regulatory Information for SODIUM NITROPRUSSIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Abraxis Pharm SODIUM NITROPRUSSIDE sodium nitroprusside INJECTABLE;INJECTION 070031-001 Jan 17, 1985 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Parenteral SODIUM NITROPRUSSIDE sodium nitroprusside INJECTABLE;INJECTION 073465-001 Mar 30, 1992 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Baxter Hlthcare SODIUM NITROPRUSSIDE sodium nitroprusside INJECTABLE;INJECTION 018581-001 Jul 28, 1982 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Akorn SODIUM NITROPRUSSIDE sodium nitroprusside INJECTABLE;INJECTION 208635-001 May 4, 2017 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Amneal Pharms Co SODIUM NITROPRUSSIDE sodium nitroprusside INJECTABLE;INJECTION 209493-001 Nov 7, 2017 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Nexus Pharms SODIUM NITROPRUSSIDE sodium nitroprusside INJECTABLE;INJECTION 207499-001 May 25, 2017 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Namigen Llc SODIUM NITROPRUSSIDE sodium nitroprusside INJECTABLE;INJECTION 207426-001 Dec 8, 2016 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
QuintilesIMS
Federal Trade Commission
Julphar
Queensland Health
Express Scripts
Cantor Fitzgerald
Teva
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot